Annexon to Present Phase 3 Data on ANX005 for Guillain-Barré at 2024 PNS Meeting

Annexon, Inc., a biopharmaceutical company focused on innovative treatments for neuroinflammatory diseases, recently announced several presentations highlighting their Guillain-Barré Syndrome (GBS) program at the 2024 Peripheral Nerve Society (PNS) Annual Meeting in Montréal, Canada. The key subject of these presentations will be the pivotal Phase 3 clinical results of ANX005, a novel therapy designed to address classical complement-mediated inflammation in the nervous system.

Guillain-Barré Syndrome is a serious condition where the body’s immune system mistakenly attacks peripheral nerves, often following an infection. This leads to rapid neuromuscular paralysis, significant morbidity, and sometimes mortality. Presently, there are no approved treatments for GBS in the U.S., making the development of effective therapies like ANX005 crucial.

ANX005 is a groundbreaking therapeutic candidate developed by Annexon. It works by selectively inhibiting C1q, a key initiator of the classical complement inflammatory cascade, thereby reducing inflammation and nerve damage. Administered intravenously, ANX005 has shown the potential to act rapidly, halting the autoimmune attack on nerve cells, which can expedite recovery in GBS patients. The therapy has received fast track and orphan drug designations from the U.S. Food and Drug Administration and orphan drug designation from the European Medicines Agency.

At the PNS Annual Meeting, several presentations will provide a comprehensive overview of the clinical progress and potential benefits of ANX005. These include an oral presentation by Dr. Quazi Deen Mohammad from the National Institute of Neuroscience in Bangladesh, detailing the design of the Phase 3 study of ANX005. Another significant event is a lunch symposium sponsored by Annexon, featuring experts like Dr. David Cornblath from Johns Hopkins University, who will discuss the groundbreaking impact of ANX005 on the GBS treatment landscape.

A flash oral presentation by Dr. Henk-André Kroon from Annexon Biosciences will compare the efficacy of ANX005 against intravenous immunoglobulin, a current standard treatment. This session will highlight the potential advantages of ANX005. Additionally, poster presentations will address the coexistence of different neuropathic conditions in GBS and the development of frameworks for comparing outcomes across diverse GBS populations.

Annexon Biosciences, listed on Nasdaq as ANNX, is committed to advancing treatments for neuroinflammatory diseases through its innovative approach of targeting upstream components of the complement system. Their lead investigational therapy, ANX005, along with other therapeutic candidates, aims to provide meaningful benefits across various autoimmune, neurodegenerative, and ophthalmic diseases. The company is actively progressing its clinical trials to bring these potential treatments to patients as swiftly as possible.

The anticipated presentations at the PNS Annual Meeting showcase the significant strides being made in the treatment of GBS and reflect Annexon’s dedication to addressing unmet medical needs in neuroinflammatory diseases. The findings and discussions from these sessions are expected to further validate the therapeutic potential of ANX005 and its role in transforming the GBS treatment landscape.

By effectively halting the classical complement cascade, ANX005 represents a promising advancement in the fight against GBS, potentially offering patients a quicker path to recovery and a return to normal life activities.